8-K: Intuitive Surgical Reports Strong Q4, Full Year 2025 Results

Intuitive Surgical announced robust preliminary fourth quarter and full year 2025 financial results, driven by significant growth in da Vinci and Ion procedures and system placements.

Summary

• Worldwide procedures (da Vinci and Ion combined) grew approximately 18% in the fourth quarter of 2025 compared to the fourth quarter of 2024, and approximately 19% for the full year 2025 compared to 2024.
• Preliminary fourth quarter 2025 revenue was approximately $2.87 billion, an increase of 19% compared to $2.41 billion in the fourth quarter of 2024.
• Preliminary full year 2025 revenue was approximately $10.06 billion, an increase of 21% compared to $8.35 billion in 2024.
• The company placed 532 da Vinci surgical systems in the fourth quarter of 2025, including 303 da Vinci 5 systems, compared to 493 systems (174 da Vinci 5) in Q4 2024.
• For the full year 2025, 1,721 da Vinci surgical systems were placed, including 870 da Vinci 5 systems, compared to 1,526 systems (362 da Vinci 5) in 2024.
• Ion endoluminal system placements were 42 in Q4 2025 (down from 69 in Q4 2024) and 195 for the full year 2025 (down from 271 in 2024), despite Ion procedures growing approximately 44% in Q4 and 51% for the full year.
• Average da Vinci system utilization increased 4% in the fourth quarter of 2025, primarily due to da Vinci 5 adoption in the U.S. and continued growth in OUS markets.
• Instruments and accessories revenue increased by 17% to approximately $1.66 billion in Q4 2025 and by 19% to approximately $6.02 billion for the full year 2025.
• Systems revenue was approximately $786 million in Q4 2025 (up 20%) and $2.47 billion for the full year 2025 (up 26%).
• Service revenue was approximately $422 million in Q4 2025 (up 21%) and $1.57 billion for the full year 2025 (up 20%).
• Total recurring revenue accounted for 81% of Q4 2025 revenue and 84% of full year 2025 revenue.
• Approximately 3,153,000 surgical procedures were performed with da Vinci systems in 2025, an 18% increase from 2024.
• U.S. general surgery procedures grew 18% and total da Vinci procedures performed outside the U.S. grew 23% in 2025.
• Fourth quarter 2025 expenses included a $70 million contribution to the Intuitive Foundation, compared to $45 million in Q4 2024.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial and operational results for both the fourth quarter and full year 2025, with significant growth in revenue, procedures, and da Vinci system placements, particularly for the new da Vinci 5 model. While Ion system placements declined, Ion procedures still grew significantly. The outlook for 2026 da Vinci procedure growth is positive, indicating continued momentum.

Positives

• Strong overall revenue growth: 19% in Q4 2025 to $2.87 billion and 21% for full year 2025 to $10.06 billion.
• Significant worldwide procedure volume growth: 18% in Q4 2025 and 19% for full year 2025.
• Da Vinci procedures grew 17% in Q4 2025 and 18% for full year 2025, totaling over 3.1 million procedures.
• Ion procedures demonstrated robust growth of 44% in Q4 2025 and 51% for full year 2025, indicating strong utilization.
• Increased da Vinci system utilization by 4% in Q4 2025, driven by da Vinci 5 adoption and OUS market growth.
• Higher da Vinci surgical system placements: 532 in Q4 2025 (up 8% YoY) and 1,721 for full year 2025 (up 13% YoY).
• Strong adoption of the new da Vinci 5 systems: 303 placed in Q4 2025 (up 183% YoY) and 870 for full year 2025 (up 140% YoY).
• Growth across diverse geographies and procedure specialties, with U.S. general surgery procedures up 18% and OUS da Vinci procedures up 23% in 2025.
• Increased average selling price for da Vinci systems by 5% in Q4 2025 and 7% for full year 2025.
• Growing installed base of da Vinci systems, reaching 11,106 as of December 31, 2025, a 12% increase year-over-year.

Negatives

• Ion endoluminal system placements decreased by 39% in Q4 2025 (42 systems) compared to Q4 2024 (69 systems).
• Full year 2025 Ion endoluminal system placements decreased by 28% (195 systems) compared to 2024 (271 systems).
• Da Vinci surgical system placements in Asia decreased by 8% in Q4 2025 (88 systems) and 16% for the full year 2025 (269 systems).
• Placements of older da Vinci X and Xi models saw significant declines, indicating a shift in demand towards the newer da Vinci 5 system.

Risks

• Preliminary financial results are unaudited and subject to change, corrections, or adjustments pending final closing procedures and independent audit.
• The overall macroeconomic environment, including tariffs, inflation, and interest rates, may impact customer spending and company costs.
• Geopolitical conflicts, such as those between Ukraine and Russia, and in the Middle East, pose risks.
• Disruption to the company's supply chain, including difficulties in obtaining a sufficient supply of materials.
• Curtailed or delayed capital spending by hospitals.
• The impact of global and regional economic and credit market conditions on healthcare spending.
• Delays in obtaining new product approvals, clearances, or certifications from regulatory authorities like the U.S. Food and Drug Administration (FDA) or comparable bodies.
• The risk of the company's inability to comply with complex FDA and other regulations, which may result in significant enforcement actions.
• Regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body.
• Healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues.
• Changes in hospital admissions and actions by payers to limit or manage surgical procedures.
• The timing and success of product development and customer acceptance of developed products.
• The results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• The company's completion of and ability to successfully integrate acquisitions.
• Intellectual property positions and litigation.
• Risks associated with the company's operations and any expansion outside of the U.S.
• Unanticipated manufacturing disruptions or the inability to meet demand for products.
• The company's reliance on sole and single-sourced suppliers.
• The results of legal proceedings to which the company is or may become a party.
• Adverse publicity regarding the company and the safety of its products and adequacy of training.
• The impact of changes to tax legislation, guidance, and interpretations.
• Changes in tariffs, trade barriers, and regulatory requirements, including changes to tariffs imposed by the U.S. on imports from various countries (e.g., Mexico for instruments/accessories, Germany for endoscopes, China for certain materials).

Future Outlook

The company expects worldwide da Vinci procedures to increase approximately 13% to 15% in 2026 compared to 2025.

Management Comments

• "We are pleased with our strong performance in the final quarter of 2025 and the full year."
• "In 2025, we saw increased adoption and utilization of our surgical platforms, expanded product clearances and indications for use across geographies, and more than 3.1 million da Vinci procedures performed."
• "As always, we remain focused on delivering the goals we share with our customers, centered on improving patient care and outcomes."

Industry Context

Intuitive Surgical continues to demonstrate its leadership in the robotic-assisted surgery market, with robust growth in da Vinci procedures and strong adoption of its latest da Vinci 5 system. The significant revenue and procedure growth rates indicate a healthy and expanding market for minimally invasive surgical technologies. While Ion system placements saw a decline, the substantial growth in Ion procedures suggests strong utilization of the existing installed base, potentially reflecting a strategic focus on maximizing the value of current systems or a shift in sales cycle dynamics for that specific platform. The overall performance reinforces the company's position as a key innovator in healthcare technology.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, revenue growth, and increased adoption of core products, potentially leading to increased share value.
• Customers (Hospitals/Healthcare Providers): Continued investment in and utilization of da Vinci systems suggest satisfaction and ongoing integration of robotic-assisted surgery into care delivery.
• Patients: Improved patient care and outcomes through minimally invasive surgery, aligning with the company's mission.
• Employees: Sustained growth and expansion could lead to job stability and opportunities within the company.

Next Steps

• Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Report fourth quarter 2025 results in more detail during a conference call on January 22, 2026.
• Complete final closing procedures and annual independent audit for the year ended December 31, 2025.
• File Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The preliminary results indicate robust growth across key financial and operational metrics, including significant revenue increases, strong procedure volume expansion for both da Vinci and Ion systems, and impressive adoption of the new da Vinci 5 platform. Despite a decline in Ion system placements, the overall procedure growth for Ion remains very strong. The company's installed base is expanding, and the forward-looking guidance for da Vinci procedures in 2026 is positive. These factors suggest continued market leadership and strong underlying business momentum, making it a compelling investment opportunity.

Keywords

Robotic-assisted surgery, da Vinci surgical systems, Ion endoluminal system, Minimally invasive care, Surgical technology, Medical devices, Healthcare technology, Financial results, Q4 2025, Full year 2025, Revenue growth, Procedure volume, System placements, ISRG, SEC filing